Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Nov, 2016 | Pages:
749 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Myelodysplastic Syndrome - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Myelodysplastic Syndrome - Pipeline Review, H2 2016, provides an overview of the Myelodysplastic Syndrome (Oncology) pipeline landscape. Myelodysplastic syndrome (MDS) is a condition that affects the bone marrow and the blood cells it produces. Myelodysplastic syndromes rarely cause signs or symptoms in the early stages of the disease. Symptoms include fatigue, shortness of breath, unusual paleness (pallor) due to anemia, easy or unusual bruising or bleeding and frequent infections. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Myelodysplastic Syndrome - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Myelodysplastic Syndrome (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Myelodysplastic Syndrome (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Myelodysplastic Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 11, 62, 55, 3, 13 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical, Discovery and Unknown stages comprises 6, 7, 2, 1 and 2 molecules, respectively.Myelodysplastic Syndrome. Myelodysplastic Syndrome (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Myelodysplastic Syndrome (Oncology). - The pipeline guide reviews pipeline therapeutics for Myelodysplastic Syndrome (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Myelodysplastic Syndrome (Oncology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Myelodysplastic Syndrome (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Myelodysplastic Syndrome (Oncology) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Myelodysplastic Syndrome (Oncology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Myelodysplastic Syndrome (Oncology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 Introduction 7 Myelodysplastic Syndrome Overview 8 Therapeutics Development 9 Myelodysplastic Syndrome - Therapeutics under Development by Companies 11 Myelodysplastic Syndrome - Therapeutics under Investigation by Universities/Institutes 18 Myelodysplastic Syndrome - Pipeline Products Glance 20 Myelodysplastic Syndrome - Products under Development by Companies 24 Myelodysplastic Syndrome - Products under Investigation by Universities/Institutes 34 Myelodysplastic Syndrome - Companies Involved in Therapeutics Development 35 Myelodysplastic Syndrome - Therapeutics Assessment 131 Drug Profiles 153 Myelodysplastic Syndrome - Dormant Projects 709 Myelodysplastic Syndrome - Discontinued Products 716 Myelodysplastic Syndrome - Product Development Milestones 718 Appendix 730
List of Tables
Number of Products under Development for Myelodysplastic Syndrome, H2 2016 27 Number of Products under Development for Myelodysplastic Syndrome - Comparative Analysis, H2 2016 28 Number of Products under Development by Companies, H2 2016 29 Number of Products under Development by Companies, H2 2016 (Contd..1) 30 Number of Products under Development by Companies, H2 2016 (Contd..2) 31 Number of Products under Development by Companies, H2 2016 (Contd..3) 32 Number of Products under Development by Companies, H2 2016 (Contd..4) 33 Number of Products under Development by Companies, H2 2016 (Contd..5) 34 Number of Products under Development by Companies, H2 2016 (Contd..6) 35 Number of Products under Investigation by Universities/Institutes, H2 2016 37 Comparative Analysis by Late Stage Development, H2 2016 38 Comparative Analysis by Clinical Stage Development, H2 2016 39 Comparative Analysis by Early Stage Development, H2 2016 40 Comparative Analysis by Unknown Stage Development, H2 2016 41 Products under Development by Companies, H2 2016 42 Products under Development by Companies, H2 2016 (Contd..1) 43 Products under Development by Companies, H2 2016 (Contd..2) 44 Products under Development by Companies, H2 2016 (Contd..3) 45 Products under Development by Companies, H2 2016 (Contd..4) 46 Products under Development by Companies, H2 2016 (Contd..5) 47 Products under Development by Companies, H2 2016 (Contd..6) 48 Products under Development by Companies, H2 2016 (Contd..7) 49 Products under Development by Companies, H2 2016 (Contd..8) 50 Products under Development by Companies, H2 2016 (Contd..9) 51 Products under Investigation by Universities/Institutes, H2 2016 52 Myelodysplastic Syndrome - Pipeline by 4SC AG, H2 2016 53 Myelodysplastic Syndrome - Pipeline by AbbVie Inc, H2 2016 54 Myelodysplastic Syndrome - Pipeline by Acceleron Pharma Inc, H2 2016 55 Myelodysplastic Syndrome - Pipeline by Actinium Pharmaceuticals Inc, H2 2016 56 Myelodysplastic Syndrome - Pipeline by Aeglea BioTherapeutics Inc, H2 2016 57 Myelodysplastic Syndrome - Pipeline by Agios Pharmaceuticals Inc, H2 2016 58 Myelodysplastic Syndrome - Pipeline by Aileron Therapeutics Inc, H2 2016 59 Myelodysplastic Syndrome - Pipeline by Altor BioScience Corp, H2 2016 60 Myelodysplastic Syndrome - Pipeline by Amgen Inc, H2 2016 61 Myelodysplastic Syndrome - Pipeline by Apogenix GmbH, H2 2016 62 Myelodysplastic Syndrome - Pipeline by Ariad Pharmaceuticals Inc, H2 2016 63 Myelodysplastic Syndrome - Pipeline by Arno Therapeutics Inc, H2 2016 64 Myelodysplastic Syndrome - Pipeline by Arog Pharmaceuticals Inc, H2 2016 65 Myelodysplastic Syndrome - Pipeline by Array BioPharma Inc, H2 2016 66 Myelodysplastic Syndrome - Pipeline by Astex Pharmaceuticals Inc, H2 2016 67 Myelodysplastic Syndrome - Pipeline by Atara Biotherapeutics Inc, H2 2016 68 Myelodysplastic Syndrome - Pipeline by Bellicum Pharmaceuticals Inc, H2 2016 69 Myelodysplastic Syndrome - Pipeline by BerGenBio AS, H2 2016 70 Myelodysplastic Syndrome - Pipeline by Bio-Path Holdings Inc, H2 2016 71 Myelodysplastic Syndrome - Pipeline by BioLineRx Ltd, H2 2016 72 Myelodysplastic Syndrome - Pipeline by BioLite Inc, H2 2016 73 Myelodysplastic Syndrome - Pipeline by Boehringer Ingelheim GmbH, H2 2016 74 Myelodysplastic Syndrome - Pipeline by Boston Biomedical Inc, H2 2016 75 Myelodysplastic Syndrome - Pipeline by Bristol-Myers Squibb Company, H2 2016 76 Myelodysplastic Syndrome - Pipeline by Cantex Pharmaceuticals Inc, H2 2016 77 Myelodysplastic Syndrome - Pipeline by Celgene Corp, H2 2016 78 Myelodysplastic Syndrome - Pipeline by Celldex Therapeutics Inc, H2 2016 79 Myelodysplastic Syndrome - Pipeline by Cellerant Therapeutics Inc, H2 2016 80 Myelodysplastic Syndrome - Pipeline by Celyad SA, H2 2016 81 Myelodysplastic Syndrome - Pipeline by Constellation Pharmaceuticals Inc, H2 2016 82 Myelodysplastic Syndrome - Pipeline by Cornerstone Pharmaceuticals Inc, H2 2016 83 Myelodysplastic Syndrome - Pipeline by CrystalGenomics Inc, H2 2016 84 Myelodysplastic Syndrome - Pipeline by CTI BioPharma Corp, H2 2016 85 Myelodysplastic Syndrome - Pipeline by Cyclacel Pharmaceuticals Inc, H2 2016 86 Myelodysplastic Syndrome - Pipeline by Daiichi Sankyo Company Ltd, H2 2016 87 Myelodysplastic Syndrome - Pipeline by DiNonA Inc., H2 2016 88 Myelodysplastic Syndrome - Pipeline by Eisai Co Ltd, H2 2016 89 Myelodysplastic Syndrome - Pipeline by Eleos Inc, H2 2016 90 Myelodysplastic Syndrome - Pipeline by Eli Lilly and Company, H2 2016 91 Myelodysplastic Syndrome - Pipeline by EpiZyme Inc, H2 2016 92 Myelodysplastic Syndrome - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 93 Myelodysplastic Syndrome - Pipeline by FORMA Therapeutics Inc, H2 2016 94 Myelodysplastic Syndrome - Pipeline by Fujifilm Corp, H2 2016 95 Myelodysplastic Syndrome - Pipeline by Gamida Cell Ltd, H2 2016 96 Myelodysplastic Syndrome - Pipeline by GlaxoSmithKline Plc, H2 2016 97 Myelodysplastic Syndrome - Pipeline by H3 Biomedicine Inc, H2 2016 98 Myelodysplastic Syndrome - Pipeline by IGF Oncology LLC, H2 2016 99 Myelodysplastic Syndrome - Pipeline by ImmunoGen Inc, H2 2016 100 Myelodysplastic Syndrome - Pipeline by Incyte Corp, H2 2016 101 Myelodysplastic Syndrome - Pipeline by Io Therapeutics Inc, H2 2016 102 Myelodysplastic Syndrome - Pipeline by Jazz Pharmaceuticals Plc, H2 2016 103 Myelodysplastic Syndrome - Pipeline by Jiangsu Hansoh Pharmaceutical Co Ltd, H2 2016 104 Myelodysplastic Syndrome - Pipeline by Johnson & Johnson, H2 2016 105 Myelodysplastic Syndrome - Pipeline by Johnson & Johnson Pharmaceutical Research & Development, L.L.C., H2 2016 106 Myelodysplastic Syndrome - Pipeline by Juno Therapeutics Inc, H2 2016 107 Myelodysplastic Syndrome - Pipeline by JW Pharmaceutical Corp, H2 2016 108 Myelodysplastic Syndrome - Pipeline by Kainos Medicine Inc, H2 2016 109 Myelodysplastic Syndrome - Pipeline by KaloBios Pharmaceuticals Inc, H2 2016 110 Myelodysplastic Syndrome - Pipeline by Karyopharm Therapeutics Inc, H2 2016 111 Myelodysplastic Syndrome - Pipeline by Kiadis Pharma NV, H2 2016 112 Myelodysplastic Syndrome - Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2016 113 Myelodysplastic Syndrome - Pipeline by La Jolla Pharmaceutical Company, H2 2016 114 Myelodysplastic Syndrome - Pipeline by Lixte Biotechnology Holdings Inc, H2 2016 115 Myelodysplastic Syndrome - Pipeline by MacroGenics Inc, H2 2016 116 Myelodysplastic Syndrome - Pipeline by Mateon Therapeutics Inc, H2 2016 117 Myelodysplastic Syndrome - Pipeline by medac GmbH, H2 2016 118 Myelodysplastic Syndrome - Pipeline by MedImmune LLC, H2 2016 119 Myelodysplastic Syndrome - Pipeline by MEI Pharma Inc, H2 2016 120 Myelodysplastic Syndrome - Pipeline by Merck & Co Inc, H2 2016 121 Myelodysplastic Syndrome - Pipeline by Merus NV, H2 2016 122 Myelodysplastic Syndrome - Pipeline by Mesoblast Ltd, H2 2016 123 Myelodysplastic Syndrome - Pipeline by Millennium Pharmaceuticals Inc, H2 2016 124 Myelodysplastic Syndrome - Pipeline by Mirati Therapeutics Inc, H2 2016 125 Myelodysplastic Syndrome - Pipeline by Nemucore Medical Innovations Inc, H2 2016 126 Myelodysplastic Syndrome - Pipeline by Novartis AG, H2 2016 127 Myelodysplastic Syndrome - Pipeline by Onconova Therapeutics Inc, H2 2016 128 Myelodysplastic Syndrome - Pipeline by OncoTherapy Science Inc, H2 2016 129 Myelodysplastic Syndrome - Pipeline by Opsona Therapeutics Ltd, H2 2016 130 Myelodysplastic Syndrome - Pipeline by Pfizer Inc, H2 2016 131 Myelodysplastic Syndrome - Pipeline by Pharma Mar SA, H2 2016 132 Myelodysplastic Syndrome - Pipeline by Regen BioPharma Inc, H2 2016 133 Myelodysplastic Syndrome - Pipeline by Rich Pharmaceuticals Inc, H2 2016 134 Myelodysplastic Syndrome - Pipeline by Seattle Genetics Inc, H2 2016 135 Myelodysplastic Syndrome - Pipeline by Stemline Therapeutics Inc, H2 2016 136 Myelodysplastic Syndrome - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2016 137 Myelodysplastic Syndrome - Pipeline by Sunesis Pharmaceuticals Inc, H2 2016 138 Myelodysplastic Syndrome - Pipeline by Syndax Pharmaceuticals Inc, H2 2016 139 Myelodysplastic Syndrome - Pipeline by Takara Bio Inc, H2 2016 140 Myelodysplastic Syndrome - Pipeline by Takeda Pharmaceutical Company Ltd, H2 2016 141 Myelodysplastic Syndrome - Pipeline by Targazyme Inc, H2 2016 142 Myelodysplastic Syndrome - Pipeline by TetraLogic Pharmaceuticals, H2 2016 143 Myelodysplastic Syndrome - Pipeline by Teva Pharmaceutical Industries Ltd, H2 2016 144 Myelodysplastic Syndrome - Pipeline by Toko Pharmaceutical Industries Co., Ltd., H2 2016 145 Myelodysplastic Syndrome - Pipeline by Tolero Pharmaceuticals Inc, H2 2016 146 Myelodysplastic Syndrome - Pipeline by Tragara Pharmaceuticals Inc, H2 2016 147 Myelodysplastic Syndrome - Pipeline by Trillium Therapeutics Inc, H2 2016 148 Assessment by Monotherapy Products, H2 2016 149 Assessment by Combination Products, H2 2016 150 Number of Products by Stage and Target, H2 2016 152 Number of Products by Stage and Mechanism of Action, H2 2016 160 Number of Products by Stage and Route of Administration, H2 2016 168 Number of Products by Stage and Molecule Type, H2 2016 170 Myelodysplastic Syndrome - Dormant Projects, H2 2016 727 Myelodysplastic Syndrome - Dormant Projects (Contd..1), H2 2016 728 Myelodysplastic Syndrome - Dormant Projects (Contd..2), H2 2016 729 Myelodysplastic Syndrome - Dormant Projects (Contd..3), H2 2016 730 Myelodysplastic Syndrome - Dormant Projects (Contd..4), H2 2016 731 Myelodysplastic Syndrome - Dormant Projects (Contd..5), H2 2016 732 Myelodysplastic Syndrome - Dormant Projects (Contd..6), H2 2016 733 Myelodysplastic Syndrome - Discontinued Products, H2 2016 734 Myelodysplastic Syndrome - Discontinued Products (Contd..1), H2 2016 735
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
